-September 1 to December 31, 2006 revenues were $1,523,197; accounting
for the change in fiscal year-end from August 31 2006 to December 31
2006 revenues were $4,569,591 on an annualized basis.
-Total sales more than doubled from August 31, 2005 to August 31, 2006
(from $1,891,903 to $4,112,713).
-Record volume of interactions for the four-month period ended
December 31, 2006.
-Completed previously announced Qualifying Transaction and Public
Offering on December 8, 2006.
-Working capital of $6.5 million at year end.
-Started five new pharmaceutical brands with three different clients.
MONTREAL, April 30 /CNW Telbec/ - Aptilon Corporation (TSX.V: APZ)
announced today results for the four-month period ended December 31, 2006.
Complete financial statements and MD&A are available on SEDAR at sedar.com.
Revenues for that period were $1,523,197. On an annualized basis to account
for the change in fiscal year-end to December 31, 2006, that occurred in
August 31, 2006, revenues were $4,569,591. For the twelve-month period ended
August 31, 2006, revenues were at $4,112,713 compared to $1,891,903 for the
same period in 2005 for a net increase of 117%. The current run rate of
$4,569,591 represents an increase of 141% over for the fiscal year ended
August 31, 2005.
The net loss for the four-month period ended December 31, 2006 was
$1,771,134 which represents a basic loss per share of $0.0528 (based on a
weighted average number of common shares outstanding during the period of
33,517,674. The current number of outstanding shares is 139,143,600.) The
operating loss for the four-month period ended December 31, 2006 is attributed
to additional financing for the growth of physician access and the incremental
commitment in direct sales efforts. At year end, December 31, 2006, the
company's working capital position had increased to $6,542,888.
"2006 was a significant year. We completed the previously announced
Qualifying Transaction and Public Offering and increased penetration of our
solutions to enhance interactions between pharmaceutical companies and
physicians with some of the world's top pharmaceutical brands." said Denis
Martineau, President of Aptilon. "We generated thousands of successful sales
and marketing interactions with targeted physicians via Aptilon's ReachNet
recruiting network, more than at any point in the company's history,"
"With the release of our electronic signature and sampling product and
the integration of multiple types of sales and marketing interaction solutions
under one umbrella, we intend to continue to build upon our leadership
position in this emerging market and drive further interaction growth."
Martineau adds. "In 2007, we will continue to focus on increasing
pharmaceutical sales and marketing effectiveness by providing critical access
to target physicians and increasing the volume of interactions generated on
behalf of our pharmaceutical sales and marketing clients."
Aptilon enables pharmaceutical, biotech and medical device companies to
effectively reach and interact with physicians via the Internet through its
innovative AxcelRx Live video detailing (with company reps), virtual programs,
e-Sampling, peer selling and other sales and marketing programs. Leading
healthcare companies have adopted Aptilon's "Sales Force of the Future" model,
driving tens of thousands of high-quality rep-physician interactions averaging
eight to 10 minutes in length. Aptilon provides the infrastructure necessary
for sales representatives to build physician awareness, understanding and
preference during all stages of a products life cycle, from pre-launch
education through end stage support. For more information, visit
This news release contains forward-looking information. These statements
relate to future events or future performance and reflect management's current
expectations and assumptions. Such forward-looking statements reflect
management's current beliefs and are based on information currently available
to management of Aptilon. A number of factors could cause actual events,
performance or results to differ materially from the events performance and
results discussed in the forward-looking statements. These forward-looking
statements are made as of the date hereof and Aptilon does not assume any
obligation to update or revise them to reflect new events or circumstances.
The TSX Venture Exchange has neither approved nor disapproved the
contents of this press release. The TSX Venture Exchange does not accept
responsibility for the adequacy or accuracy of this press release.
For further information:
For further information: Denis Martineau, President, Aptilon, (514)
844-8866, ext 228, email@example.com; Media Relations: Alexandra Malka,
Marketing Communication Specialist, Aptilon, (514) 844-8866, ext 239,